DNTH — Dianthus Therapeutics Inc.

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Dianthus Therapeutics Inc.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$87.42
Market Cap$4.78B
Float42.0M
Shares Outstanding54.4M
Price/Sales (TTM)2,348.04
vs. Analyst Target+43.5% to analyst PT
Operating Margin (TTM)-24486.27%
Revenue (TTM)$2.0M
Dividend RateNone
Analyst Target Price$125.46 (12 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 N/A -$74.9M -$2.0M -$73.0M
2021 $1.5M -$13.1M $1.5M -$13.1M
2022 $6.4M -$28.5M $6.4M -$29.6M
2023 $2.8M -$43.6M $2.8M -$47.8M
2024 $6.2M -$85.0M $6.2M -$101M
2025 $2.0M -$162M $2.0M -$178M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Mar 2025 $1.2M -$29.5M
Jun 2025 $193,000 -$31.6M
Sep 2025 $396,000 -$36.8M
Dec 2025 $284,000 $97.9M

Ownership & Float

Insider Ownership0.1%
Institutional Ownership98.2%
Short Float15.6%
% of All Funds Holding1.86%
Number of Funds Holding144

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$80.10Near-term / short-term trend
Weekly40-Week SMA$48.19Medium-term trend
Weekly80-Week SMA$34.89Cyclical trend (business cycle)
Weekly200-Week SMA$25.15Secular trend (multi-year)
Monthly10-Month SMA$55.08Near-term monthly trend
Monthly20-Month SMA$38.24Medium-term monthly trend
Monthly40-Month SMA$28.15Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$54.00 support 2.28x 1 months ago
$42.00 support 1.57x 3 months ago
$34.60 support 1.49x 5 months ago
$23.40 support 2.91x 7 months ago

Historical Earnings Reactions (31 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.96% 0.50% 58.06% 7.86% -5.45%
1 Day 1.44% 0.10% 51.61% 14.32% -8.00%
1 Week -0.72% 0.62% 51.61% 28.20% -21.87%
2 Weeks -1.24% -0.86% 45.16% 29.17% -36.38%
1 Month -0.87% -1.47% 35.48% 97.91% -43.51%

Next earnings: May 11, 2026

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan17.4%75.0%8
Feb22.5%62.5%8
Mar4.8%50.0%8
Apr-5.0%37.5%8
May-5.5%57.1%7
Jun1.7%71.4%7
Jul3.0%62.5%8
Aug-1.2%50.0%8
Sep5.6%37.5%8
Oct-9.4%25.0%8
Nov4.3%50.0%8
Dec-15.8%25.0%8

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.01% 41.8% 371
Tuesday -0.18% 44.5% 407
Wednesday 0.37% 48.9% 403
Thursday -0.41% 42.9% 396
Friday 0.70% 49.2% 398

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 98.2%

Insider Transactions — Smart Summary

Total insider ownership: 0.1%

12-Month Insider Activity Summary

Total Filings11
Net Value-$28.4M
Net Shares Change0
% of Float0.0%
C-Suite Filings8
Clusters Detected1

Key Insiders

NameTitleNet ValueFilingsActivity
Savitz Ryan EVP, CFO and CBO -$9.5M 3 N/A
Garcia Marino CEO AND PRESIDENT -$9.2M 1 N/A
Randhawa Simrat EVP, Head of RandD -$6.5M 2 N/A
CARR EDWARD CHIEF ACCOUNTING OFFICER -$2.7M 1 N/A
Soteropoulos Paula -$2.0M 3 N/A

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2026-03-13 – 2026-03-26 4 4 -$15.9M 3 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-04-01 Savitz Ryan EVP, CFO and CBO -$8.1M Transaction at $47.37, now +84.5%
2026-03-13 Garcia Marino CEO AND PRESIDENT -$9.2M Transaction at $44.09, now +98.3%
2026-03-13 Randhawa Simrat EVP, Head of RandD -$2.1M Transaction at $49.82, now +75.5%
2026-03-13 CARR EDWARD CHIEF ACCOUNTING OFFICER -$2.7M Transaction at $50.97, now +71.5%
2026-03-26 Soteropoulos Paula -$1.9M Transaction at $43.24, now +102.2%
2025-11-14 Randhawa Simrat EVP, Head of RandD -$4.4M Transaction at $26.40, now +231.1%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Dianthus Therapeutics Inc. (DNTH) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for DNTH on Trend Edge →